imatinib mesylate has been researched along with Epithelial Ovarian Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, L; Dai, W; Gu, T; Wang, D; Wang, H; Zhu, M | 1 |
| Amadori, A; Frezzini, S; Leone, K; Mazzoldi, EL; Nicoletto, MO; Pagotto, A; Pastò, A; Pavan, S; Pilotto, G | 1 |
2 other study(ies) available for imatinib mesylate and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
AADAC promotes therapeutic activity of cisplatin and imatinib against ovarian cancer cells.
Topics: Antineoplastic Agents; Carboxylic Ester Hydrolases; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Female; Humans; Imatinib Mesylate; Ovarian Neoplasms | 2022 |
A juxtacrine/paracrine loop between C-Kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Differentiation; Cell Proliferation; Cell Survival; Female; Fibroblasts; HEK293 Cells; Humans; Imatinib Mesylate; Macrophages; Neoplastic Stem Cells; Ovarian Neoplasms; Paracrine Communication; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction; Stem Cell Factor; Tumor Microenvironment | 2019 |